Oncolytic Virotherapy

"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.

Descriptor ID	D050130
MeSH Number(s)	E02.095.601
Concept/Terms	Oncolytic Virotherapy Oncolytic Virotherapy Oncolytic Virotherapies Virotherapies, Oncolytic Virotherapy, Oncolytic Oncolytic Virus Therapy Oncolytic Virus Therapies Therapies, Oncolytic Virus Therapy, Oncolytic Virus Virus Therapies, Oncolytic Virus Therapy, Oncolytic

Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Biological Therapy [E02.095]
Oncolytic Virotherapy [E02.095.601]

Below are MeSH descriptors whose meaning is related to "Oncolytic Virotherapy".

Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.

Bar chart showing 105 publications over 18 distinct years, with a maximum of 12 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	1	2
2006	5	1	6
2007	5	1	6
2008	9	3	12
2009	4	1	5
2010	4	1	5
2011	1	0	1
2012	4	1	5
2013	2	1	3
2014	5	2	7
2015	3	3	6
2016	6	2	8
2017	9	1	10
2018	4	0	4
2019	5	1	6
2020	6	1	7
2021	7	2	9
2022	3	0	3

Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.

de la Nava D, Selvi KM, Alonso MM. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Front Immunol. 2022; 13:866892.

View in: PubMed
Laspidea V, Puigdelloses M, Labiano S, Marrodán L, Garcia-Moure M, Zalacain M, Gonzalez-Huarriz M, Martínez-Vélez N, Ausejo-Mauleon I, de la Nava D, Herrador-Cañete G, Marco-Sanz J, Guruceaga E, de Andrea CE, Villalba M, Becher O, Squatrito M, Matía V, Gállego Pérez-Larraya J, Patiño-García A, Gupta S, Gomez-Manzano C, Fueyo J, Alonso MM. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight. 2022 04 08; 7(7).

View in: PubMed
Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.

View in: PubMed
Martinez-Velez N, Laspidea V, Zalacain M, Labiano S, García-Moure M, Puigdelloses M, Marrodan L, Gonzalez-Huarriz M, Herrador G, de la Nava D, Ausejo-Mauleon I, Fueyo J, Gomez-Manzano C, Patiño-García A, Alonso MM. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Mol Cancer Ther. 2022 03 01; 21(3):471-480.

View in: PubMed
Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242.

View in: PubMed
Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021 11 02; 23(11):1911-1921.

View in: PubMed
Ravirala D, Mistretta B, Gunaratne PH, Pei G, Zhao Z, Zhang X. Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy. J Immunother Cancer. 2021 07; 9(7).

View in: PubMed
Fueyo J, Gomez-Manzano C, Lang FF, Alonso MM. Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. Lancet Oncol. 2021 08; 22(8):1049-1051.

View in: PubMed
Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).

View in: PubMed
Shin DH, Nguyen T, Ozpolat B, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J Immunother Cancer. 2021 04; 9(4).

View in: PubMed

People

Explore

Similar Concepts

Top Journals